Dong Cheng is a seasoned professional with over 20 years of extensive experience in the pharmaceutical industry, specializing in cardiovascular (CV), metabolic diseases, and fibrosis. As the Director and Eliquis Lead for US Medical Cardiovascular & Established Brands at Bristol Myers Squibb, Dong plays a...
Dong Cheng is a seasoned professional with over 20 years of extensive experience in the pharmaceutical industry, specializing in cardiovascular (CV), metabolic diseases, and fibrosis. As the Director and Eliquis Lead for US Medical Cardiovascular & Established Brands at Bristol Myers Squibb, Dong plays a pivotal role in shaping the medical evidence generation and communication strategy for Eliquis, a leading anticoagulant. His expertise in real-world evidence (RWE) and translational medicine allows him to effectively bridge the gap between clinical research and practical application, ensuring that Eliquis remains at the forefront of treatment options for patients.
In his current role, Dong is responsible for the development and execution of integrated strategies that not only enhance the understanding of Eliquis's clinical benefits but also address market access challenges. His leadership in identifying two promising clinical candidates for the treatment of non-alcoholic steatohepatitis (NASH) during proof-of-concept trials showcases his commitment to advancing therapeutic options in metabolic diseases. Dong’s proficiency in biomarker discovery and clinical development further strengthens his ability to drive innovative research initiatives.
Additionally, Dong actively engages with advisory boards, leveraging his extensive network to gather insights that inform strategic decisions. His ability to lead change within the organization and foster collaboration across multidisciplinary teams is a testament to his strong leadership skills. With a deep understanding of life sciences and a passion for improving patient outcomes, Dong Cheng continues to make significant contributions to the field, positioning Bristol Myers Squibb as a leader in the development of cutting-edge therapies.
